Glomerular galactose-deficient IgA1 and apoptosis inhibitor of macrophage staining in secondary IgA nephropathy associated with alcoholic cirrhosis

Pattrapornpisut P, Avila-Casado C, Reich HN (2021) IgA nephropathy: core curriculum 2021. Am J Kidney Dis 78:429–441. https://doi.org/10.1053/j.ajkd.2021.01.024

Article  CAS  PubMed  Google Scholar 

Wang M, Lv J, Zhang X, Chen P, Zhao M, Zhang H (2019) Secondary IgA nephropathy shares the same immune features with primary IgA nephropathy. Kidney Int Rep 5:165–172. https://doi.org/10.1016/j.ekir.2019.10.012

Article  PubMed  PubMed Central  Google Scholar 

Hommos MS, El-Zoghby ZM (2017) Renal outcomes in patients with IgA nephropathy undergoing liver transplant: a retrospective cohort study. Transplant Direct 3:e193. https://doi.org/10.1097/TXD.0000000000000708

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takada D, Sumida K, Sekine A, Hazue R, Yamanouchi M, Suwabe T, Hayami N, Hoshino J, Sawa N, Takaichi K, Fujii T, Ohashi K, Ubara Y (2017) IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis. BMC Nephrol 18:362. https://doi.org/10.1186/s12882-017-0769-1

Article  PubMed  PubMed Central  Google Scholar 

Suzuki H, Novak J (2021) IgA glycosylation and immune complex formation in IgAN. Semin Immunopathol 43:669–678. https://doi.org/10.1007/s00281-021-00883-8

Article  CAS  PubMed  Google Scholar 

Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y (2018) IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93:700–705. https://doi.org/10.1016/j.kint.2017.10.019

Article  CAS  PubMed  Google Scholar 

Cassol CA, Bott C, Nadasdy GM, Alberton V, Malvar A, Nagaraja HN, Nadasdy T, Rovin BH, Satoskar AA (2020) Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. Nephrol Dial Transplant 35:2123–2129. https://doi.org/10.1093/ndt/gfz152

Article  CAS  PubMed  Google Scholar 

Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y (2020) Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 31:2013–2024. https://doi.org/10.1681/ASN.2019100987

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC (2011) Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 80:1352–1363. https://doi.org/10.1038/ki.2011.276

Article  CAS  PubMed  Google Scholar 

Oshima M, Iwata Y, Furuichi K, Sakai N, Shimizu M, Hara A, Kitajima S, Toyama T, Shinozaki Y, Sagara A, Umeda E, Kaneko S, Arai S, Miyazaki T, Wada T (2017) Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction. Clin Exp Nephrol 21:35–42. https://doi.org/10.1007/s10157-016-1240-5

Article  CAS  PubMed  Google Scholar 

Ronsin C, Braud P, Kandel-Aznar C, Dujardin A, Petit C, Larmet D, Garandeau C, Deltombe C, Le Clech A, Leman C, Blancho G, Schurder J, Couvrat-Desvergnes G, Ville S (2024) Clinical presentation, pathological spectrum, and outcomes of alcoholic cirrhosis-related IgA nephropathy. Kidney Int Rep 9:1369–1378. https://doi.org/10.1016/j.ekir.2024.02.1397

Article  PubMed  PubMed Central  Google Scholar 

Yoshimura Y, Ikuma D, Mizuno H, Kono K, Kinowaki K, Sugimoto H, Kamido H, Sawada Y, Mizuta M, Kurihara S, Oba Y, Yamanouchi M, Suwabe T, Ohashi K, Ubara Y, Sawa N (2024) Efficacy of SGLT2 inhibitors in IgA nephropathy associated with alcoholic liver cirrhosis accompanied by nephrotic syndrome: a case report. Front Nephrol 3:1331757. https://doi.org/10.3389/fneph.2023.1331757

Article  PubMed  PubMed Central  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1–S276. https://doi.org/10.1016/j.kint.2021.05.021

Article  Google Scholar 

Comments (0)

No login
gif